Glycomine Inc.
- Address
- 733 Industrial Road
Sponsor Overview
Specializations
Congenital Disorders of Glycosylation
Glycomine Inc. focuses on PMM2-CDG, a rare inherited metabolic disorder affecting protein glycosylation and multiple organ systems.
- PMM2-CDG
- Inherited metabolic disease
- Glycosylation defects
The sponsor’s clinical activity centers on this ultra-rare disease area, with research spanning pediatric, adolescent, and adult populations.
Neurological Manifestations
Its trials place particular emphasis on ataxia and related neurological impairment associated with PMM2-CDG.
- Ataxia assessment
- Neuromotor function
- Clinical severity measures
Clinical evaluation in this area reflects interest in motor coordination and disease-related functional limitations.
Rare Disease Therapeutics
Glycomine Inc. is actively involved in therapeutic development for rare genetic disorders, with a strong focus on treatment options for PMM2-CDG.
- Rare disease treatment
- Genetic disorder therapy
- Long-term disease management
Its research portfolio includes ongoing studies evaluating safety, tolerability, and clinical effects in this specialized therapeutic setting.
Metabolic and Multisystem Disease Care
The sponsor’s studies also reflect interest in the broader systemic consequences of PMM2-CDG, a disorder that can affect neurological and metabolic function together.
- Multisystem involvement
- Metabolic disease
- Functional outcome monitoring
Research activity in this area supports clinical understanding of disease burden across different age groups and care settings.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of Intravenous GLM101 in PMM2-CDG: A Phase 2b, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study |  Belgium Czechia France Germany Italy Poland Portugal Spain | Not Recruiting |
| Phase 2 Study on Pharmacodynamics, Safety, and Pharmacokinetics of GLM101 in PMM2-CDG Patients | Spain | Not Recruiting |
| Safety and Efficacy Evaluation of Intravenous GLM101 in Patients with PMM2-CDG: A Phase 2 Open-Label Extension Study | Czechia France Germany Italy Portugal Spain | Recruiting |
Data & Insights
This sponsor works with 3 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 11 sites across their trial portfolio.
Therapeutic Focus
- 1.Nutritional and Metabolic Diseases3 trials211 other sponsors
Partnered Research Centres
11 centres- Address
- Via Paradisa 2, 56124 Pisa
- Address
- Via Santa Sofia 78, 95123 Catania
- Address
- Largo Professor Abel Salazar, 4050-011 Porto
- Address
- 100 Boulevard Du General Leclerc, 92110 Clichy
- Address
- 149 Rue De Sevres, 75015 Paris
- Address
- Passeig De Sant Joan De Deu 2, 08950 Esplugues de Llobregat
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Glycomine Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.